Navigation Links
New Study Explores Impact of More Uniform Distribution of Endovascular Coils in Cerebral Aneurysm Treatment
Date:6/21/2011

RAYNHAM, Mass., June 21, 2011 /PRNewswire/ -- A new study published in the June edition of the Journal of NeuroInterventional Surgery(1) highlights that a more uniform distribution of endovascular coils may help in the treatment of cerebral aneurysms, it was reported by Codman & Shurtleff, Inc. (Codman), a global neurovascular and neuroscience company.  Codman's DELTAPAQ™ endovascular microcoils were used in the study.

Study authors found that the novel triangular primary wind design of DELTAPAQ™ endovascular microcoils achieved a tighter packing density and a more uniform distribution of the coil mass across the aneurysm dome in comparison with helical and complex endovascular microcoils.  DELTAPAQ coils were also more likely to have the highest rate of angiographic occlusion.  

Researchers concluded that the evaluation of emerging coil technologies with respect to treatment durability may be well served by an assessment of their uniformity of distribution within an aneurysm, in addition to the traditional packing density and angiographic occlusion scoring methods.  

"This study suggests that the uniformity across the dome of the aneurysm may play an important role in enhancing the durability of endovascular treatment and is an important area for further study and confirmation," said Bernard R. Bendok, MD, study co-author and Associate Professor of Neurological Surgery and Radiology at Northwestern University's Feinberg School of Medicine.*  "The application of a coil uniformity model may provide valuable design information."  

Study authors constructed silicone aneurysm models and devised an assessment tool to objectively measure the coil uniformity index, which when combined with the degree of angiographic occlusion and packing density, can provide valuable information regarding coil behavior.

In the in vitro study, DELTAPAQ coils were more uniformly distributed in the dome of t
'/>"/>

SOURCE Codman & Shurtleff, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... March 29, 2015  Three-month paliperidone palmitate, an ... compared to placebo in patients with schizophrenia, according ... this week in the Journal of ... . Results of the study served as ... (NDA) filing for three-month paliperidone palmitate injection to ...
(Date:3/27/2015)... March 27, 2015 BioCorRx, Inc. ( ... Ana, California is a healthcare solutions organization, which ... estimated at $22 billion in the U.S. alone. The Company ... FDA-approved Naltrexone in a specially compounded form for outpatient surgical ... and New Zealand ) to ...
(Date:3/27/2015)... CHAPEL HILL, N.C. , March 27, 2015 /PRNewswire/ ... function is essential to meeting challenges in clinical development, ... and face tighter regulations, the Medical Affairs function is ... charted by mature markets. According to ... market study participants have a group dedicated to Medical ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
... Feb. 2, 2011 WaferGen Biosystems, Inc. (OTC Bulletin ... analysis systems, today announced that it will present an overview of ... in New York City at the Waldorf Astoria Hotel, Tuesday, February ... webcast live and archived for 90 days and may be accessed ...
... 2011 Reportlinker.com announces that a new market research ... US Prebiotics Industry ... And European markets for Prebiotics in Metric Tons and ... the following product segments: Mannan-Oligosaccharide (MOS), Fructans (Fructo-Oligosaccaride (FOS), ...
Cached Medicine Technology:WaferGen to Present at 13th Annual BIO CEO and Investor Conference 2US Prebiotics Industry 2US Prebiotics Industry 3US Prebiotics Industry 4US Prebiotics Industry 5US Prebiotics Industry 6US Prebiotics Industry 7
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... correlate with a history of shoulder and elbow injuries, according ... for Sports Medicine’s ( AOSSM ) Specialty Day. , “Our ... associated with a 20% increase in likelihood of a history ... is associated with a 12% increase likelihood of a history ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Delaying ... not be necessary, according to research presented today at ... ) Specialty Day. , “Our study compared results for ... who underwent an additional glenohumeral joint capsule release procedure ... George Murrell MD, PhD, lead author from St. George ...
(Date:3/28/2015)... Francisco, California (PRWEB) March 28, 2015 Andrew ... for original 1960's Who psychedelic concert posters. The Who and ... New York on August 2, 1968. According to Hawley, “The ... playing many concert halls and college campuses. Perhaps the most ... performance with Jim Morrison and the Doors on August 2, ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Healthpointe’s otolaryngologists, ... nose and throat disorders, are now offering a ... common issue which is characterized by the presence of ... in 5 people, tinnitus is a prevalent symptom that ... while it is non-fatal, tinnitus can impede a person’s ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s ... the Chesapeake Conference Center in Chesapeake, Virginia. Each year, ... for women in the Hampton Roads region. The 2015 ... Lives. Women grow stronger through sharing their stories and ... year the WWC™ theme is T-talk where we will share ...
Breaking Medicine News(10 mins):Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... Consumers need answers to questions that loom large ... is at risk.A new discussion forum launching this week ... ask tough questions and get straight answers about health ... options after a job loss."People who lose their jobs ...
... news release, Your Finances or a Facelift? It,s ... & Co Ltd over PR Newswire, we are advised ... press release was issued inadvertently. The complete, corrected release ... To DownsizeLeading Image Enhancement Coach Wendy Lewis Explains the ...
... To prevent the rejection of newly transplanted ... weaken their entire immune systems. Such potentially life-saving ... to life-threatening infections. , Now researchers at ... School of Medicine and the UNC Lineberger Comprehensive ...
... 11, 2009 "The House of Representatives and the ... ,down payment, on health care reform in the economic ... the American College of Physicians, said today. ... agreement that will provide adequate funding for critical health ...
... Feb. 11 Mesa Laboratories, Inc. (Nasdaq: ... of Directors has declared a regular quarterly cash ... stock, payable on March 16, 2009 to shareholders ... February 27, 2009.Mesa Laboratories develops, acquires, manufactures and ...
... Fresenius Kabi Pty Ltd, one of Australia,s fastest growing ... System (Robotic IV Automation) - a self-contained unit for ... Systems (IH Systems) to consolidate its IV preparation. Pharmatel ... unit in June 2009. , The RIVA System and ...
Cached Medicine News:Health News:C4CC Education Fund Launches Discussion Forum for Consumers With Health Insurance Questions 2Health News:Your Facelift or Your Finances? It's Time To Downsize 2Health News:UNC study hints at new approaches to prevent transplant rejection 2Health News:UNC study hints at new approaches to prevent transplant rejection 3Health News:ACP commends Congress for including health care reform in economic stimulus legislation 2Health News:Australia's Leading Oncology Drug Compounder Chooses RIVA System 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: